|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 239/47 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| A61K 31/505 | (2006.01) |
| (11) | Number of the document | 3972960 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20729201.2 |
| Date of filing the European patent application | 2020-05-20 | |
| (97) | Date of publication of the European application | 2022-03-30 |
| (45) | Date of publication and mention of the grant of the patent | 2025-12-24 |
| (46) | Date of publication of the claims translation | 2026-03-25 |
| (86) | Number | PCT/IB2020/054752 |
| Date | 2020-05-20 |
| (87) | Number | WO 2020/234779 |
| Date | 2020-11-26 |
| (30) | Number | Date | Country code |
| 201962851986 P | 2019-05-23 | US |
| (72) |
ANGST, Daniela , CH
KORDIKOWSKI, Andreas , CH
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kristalinės BTK inhibitoriaus formos |
| CRYSTALLINE FORMS OF A BTK INHIBITOR |
| Payment date | Validity (years) | Amount | |
| 2026-03-20 | 7 | 162.00 EUR |
| 2027-05-20 |